Tyra Biosciences Says FDA Granted Rare Pediatric Disease Designation To TYRA-300, An Oral FGFR3 Selective Inhibitor, For Treatment Of Achondroplasia, The Most Common Form Of Dwarfism With Limited Therapeutic Options
Benzinga Newsdesk - Feb 1, 2024, 5:33PM